# FDA approves first drug for neurological symptoms in Type 3 Gaucher disease

Adults and children weighing at least 15 kg are eligible for Infilbray. In a 52-week trial, the tablets outperformed enzyme replacement therapy on a combined measure of muscle coordination and thinking.

Science · By ITANU Magazine newsroom · Published 2026-11-19T05:31:20.000Z · 1 min read

## Key points

- Infilbray reaches the brain and reduces the buildup of fatty substances there.
- The trial enrolled 43 patients aged 12 or older whose disease outside the nervous system had stabilized with enzyme replacement therapy.
- The FDA cited reports of serious psychiatric effects, including suicidal thoughts and behavior.

On 18 November the US Food and Drug Administration approved Infilbray, the first drug for neurological symptoms in Type 3 Gaucher disease [1]. The approval covers venglustat tablets for adults and children weighing at least 15 kg [1].

In this rare inherited condition, an enzyme fails to break down certain fatty substances properly, allowing them to build up in the brain and elsewhere in the body [1]. Patients can develop problems with balance, speech and memory that worsen over time [1]. Infilbray can pass from the bloodstream into the brain and reduce the buildup there [1].

The phase 3 trial, called LEAP2MONO, enrolled 43 patients aged 12 or older whose disease outside the nervous system had stabilized with enzyme replacement therapy [2]. Researchers randomly assigned participants to take a tablet daily or receive enzyme replacement by infusion every two weeks [1].

After 52 weeks, the tablet group did better on a measure that combined tests of muscle control and coordination with an assessment of thinking [1]. Sanofi reported that the difference was statistically significant (p=0.0137) [3].

The FDA listed digestive symptoms and changes in mood among the most commonly reported side effects [1]. The agency also cited reports of serious psychiatric effects, including suicidal thoughts and behavior [1].

## Sources

1. [FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease), U.S. Food and Drug Administration (Primary)
2. [FDA Approves Venglustat, First Treatment for Neurological Symptoms of GD3](https://www.pharmacytimes.com/view/fda-approves-venglustat-first-treatment-for-neurological-symptoms-of-gd3), Pharmacy Times (Independent)
3. [Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease](https://www.news.sanofi.us/2026-11-18-Sanofis-Infilbray-approved-in-the-US-as-the-first-medicine-to-treat-neurological-manifestations-of-Type-3-Gaucher-disease), Sanofi (Primary)

ITANU’s newsroom system produced this article with AI and checked it against the sources listed above.

Canonical: https://itanu.org/magazine/fda-approves-first-drug-neurological-symptoms-gaucher-disease-oomhwxh6/
